The neuropharmacology of abnormal involuntary movement disorders (the dyskinesias).
D000109:Acetylcholine / Q000378:metabolism; D000818:Animals; D001679:Biogenic Amines / Q000134:cerebrospinal fluid / Q000378:metabolism*; D001921:Brain / Q000378:metabolism*; D001923:Brain Chemistry; D002090:Butyrophenones / Q000494:pharmacology; D003342:Corpus Striatum / Q000473:pathology; D004298:Dopamine / Q000378:metabolism; D004422:Dystonia Musculorum Deformans / Q000378:metabolism; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism / Q000473:pathology; D007980:Levodopa / Q000009:adverse effects / Q000494:pharmacology; D009069:Movement Disorders / Q000139:chemically induced / Q000378:metabolism*; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D010640:Phenothiazines / Q000494:pharmacology; D012701:Serotonin / Q000378:metabolism; D005879:Tourette Syndrome / Q000378:metabolism; D014149:Tranquilizing Agents / Q000009:adverse effects / Q000494:pharmacology
D001679:Biogenic Amines; D002090:Butyrophenones; D010640:Phenothiazines; D014149:Tranquilizing Agents; D012701:Serotonin; D007980:Levodopa; D000109:Acetylcholine; D004298:Dopamine